Open Access Open Access  Restricted Access Subscription or Fee Access

Neurodegenerative Brain Disorder: Molecular Mechanism of Alzheimer's Disease

Gaurav Singh

Abstract


Alzheimer's disease (AD) is indeed a serious neurological brain disorder defined by the deposition of amyloid-beta plaques and neurofibrillary tangles with in brain, resulting in neural fragmentation, synapses malfunction, and leading to cell death, all of which lead to dementia. Although various FDA-approved drugs are commercially accessible, such as Donepezil, Galantamine and Rivastigmine, their use only relieves signs but does not treat the disease. Many people suffer from this ailment as they get older. The cost of fighting the disease is usually quite high. The research looks at biochemical processes in neurons both in healthy and Alzheimer's patients, with consequences for the tau hypothesis, amyloid hypothesis, dementia risk factors, increased lipid peroxidation, and neuronal injury, all of which are intertwined with neurodegenerative. A rapid assessment of important biomarkers for clinical diagnosis and therapeutic drugs and problems in reaching therapeutic targets in reducing disease pathology is conducted. This review considers the drawbacks of medications' inability to achieve aims, as well as their adverse effects and toxicities. Positively, this study focuses on the advantages of combining a novel neural stem cell therapy strategy with nanotechnology-based drug delivery devices to overcome the blood-brain barrier and improve treatment effectiveness. Specifically, this review will focus on the natural, non-therapeutic able to heal impact of traumatic exercise on various model organisms, as well as the effect of safe neuromodulation treatments in humans, such as repetitive Transcranial Magnetic Stimulation (rTMS) and transcranial Electrical Stimulation (tES), on disease pathologies that are prominent in boosting mode is activated.


Keywords


Neurodegenerative, Brain disorder, Molecular mechanism, Disease, Alzheimer

Full Text:

PDF

References


Brooks WS, Martins RN, DeVoecht J. A mutation in codon 717 of the amyloid precursor protein gene in an Australian family with Alzheimer`s disease. Neurosci Lett. 1995; 199: 183–186.

Campion D, Brice A, Hannequin D. The French Alzheimer’s disease study group: No founder effect in three novel Alzheimer’s disease families with APP 717 Val-Ile mutation. J Med Genet 1996; 33: 661–664.

Chartier-Harlin MC, Crawford F, Houldon H. Early-onset Alzheimer`s disease caused by mutations at codon 717 of the b-amyloid precursor protein gene. Nature. 1991; 353: 844–846.

Cruts M, Hendriks L, Van Broeckhoven C. The presenilin genes: a new gene family involved in Alzheimer’s disease pathology. Hum Mol Genet. 1996; 5: 1449–1455.

Fidani L, Goate A. Mutations in APP and their role in beta-amyloid deposition. Prog Clin Biol Res 1992; 379: 195–214.

Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Comm 1984; 120: 885–890.

Goate A, Chartier-Harlin MC, Mullan M. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer`s disease. Nature. 1991; 349: 704–706.

Hardy J. Amyloid the presenilins and Alzheimer’s disease. Trends Neurosci. 1997; 20: 154–159.

Helisalmi S. Molecular genetics of Alzheimer's disease with special emphasis on presenilin, amyloid beta precursor protein and apolipoprotein E genes. Series of Reports, Department of Neurology, University of Kuopio. 1997; 44.

Hendriks L, van Duijn CM, Cras P. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the b-amyloid precursor protein gene. Nature Genet. 1992; 1: 218–221.

Hutton M, Hardy J. The presenilins and Alzheimer’s disease. Hum Mol Genet. 1997; 6: 1639–1646.

Karlinsky H, Vaula G, Haines JL. Molecular and prospective phenotypic charaterization of a pedigree with familial Alzheimer`s disease and a missense mutation in codon 717 of the b-amyloid precursor protein gene. Neurology. 1992; 42: 1445–1453.

Lendon CL, Ashall F, Goate AM. Exploring the etiology of Alzheimer’s disease using molecular genetics. JAMA. 1997; 277: 825–831.

Levy-Lahad E, Wasco W, Poorkaj P. Candidate gene for chromosome 1 familial Alzheimer’s disease locus. Science. 1995b; 269: 973–977.

Levy-Lahad E, Wijsman EM, Nemens E. A familial Alzheimer`s disease locus on chromosome 1. Science 1995c; 269: 970–973.

Mann DAM. The pathological association between Down syndrome and Alzheimer’s disease. Mech Age Dev. 1985; 43: 99–136.

Matsumura Y, Kitamura E, Miyoshi K. Japanese siblings with missense mutation (717Val®lle) in amyloid precursor protein of early-onset Alzheimer`s disease. Neurology. 1996; 46: 1721–1723.

Mullan M, Crawford F, Axelman K. A pathogenic mutation for probable Alzheimer`s disease in the APP gene at the N-terminus of b-amyloid. Nature Genet. 1992; 1: 345–347.




DOI: https://doi.org/10.37628/ijmb.v8i1.759

Refbacks

  • There are currently no refbacks.